BTP Stock Chart & Stats
€0.01
<€0.01(14.29%)
At close: 4:00 PM EST
€0.01
<€0.01(14.29%)
Day’s Range― - ―
52-Week Range€0.24 - €2.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.05K
Market Cap
€8.85M
Enterprise Value€106.98M
Total Cash (Recent Filing)€43.90M
Total Debt (Recent Filing)€100.00K
Price to Earnings (P/E)―
Beta-6.39
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding26,360,670
10 Day Avg. Volume0
30 Day Avg. Volume1,051
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)111.47
Price to Sales (P/S)0.00
P/FCF Ratio-191.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€1.93M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces fixed financial obligations and preserves flexibility while the company advances its therapeutic pipeline. Compared with a more leveraged structure, the near-zero debt-to-equity position lowers refinancing pressure and leaves fewer lender claims on future resources.
Narrowing Net LossesThe multi-year reduction in net losses indicates that financial performance is moving in a less adverse direction, even though profitability remains negative. If sustained, better cost control could extend the company’s runway and reduce the pace at which additional funding may be required.
Improving Cash-burn TrendOperating cash outflows have become materially less negative over several reporting periods, showing progress in controlling cash consumption. This does not yet establish self-funding, but continued improvement could preserve capital longer and support ongoing development activity with less near-term financial strain.
Bears Say
No Operating RevenueZero reported revenue means the business has not yet demonstrated commercial monetization of its therapeutic pipeline. Without recurring product, collaboration, milestone, or royalty income reflected in the results, financial support remains dependent on future development success and external funding.
Persistent Cash ConsumptionContinued negative operating and free cash flow shows that the company is consuming capital rather than funding operations internally. This can constrain the pace of clinical development and create a lasting need for financing unless revenue generation or partnership proceeds become established.
Declining And Volatile EquityThe decline in equity alongside strongly negative returns indicates that ongoing losses are eroding the company’s capital base. If this pattern persists, financing effects and potential dilution may become increasingly important, reducing financial resilience and limiting flexibility for pipeline investment.
Active Biotech AB News
BTP FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest stock price was €0.24 and its highest was €2.40 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is €8.85M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is Nov 05, 2026 which is in 7 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on Aug 20, 2026. The company reported -€0.035 earnings per share for the quarter.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 26,360,670 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of -€0.035 in its last earnings report. Following the earnings report the stock price went up 0.481%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in DE:BTP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
Oncopeptides AB
―
SynAct Pharma AB
―
Cantargia AB
―